Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track TVGN with free AI briefings, catalyst countdowns, and dilution alerts.

TVGN · Tevogen Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$1.1M Cash on Hand
1.1mo Cash Runway
Follow TVGN by email Get an email when TVGN reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about TVGN, unsubscribe in one click. Privacy

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Cytotoxic T-Lymphocyte Covid19 Phase 1 · NCT04765449 Completed

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

TVGN holds $1.1M in cash and short-term investments (as of Jun 30, 2026) and burns about $2.9M/quarter from operations, an estimated runway of 1.1 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 55 · Elevated

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when TVGN files for a raise →

👥 Who Owns TVGN

Insiders 94.1% Institutions (37 holders) 1.8% Public and other holders 4.1%
HolderTypeShares% of sharesAs of
Ryan H. Saadi
Chief Executive Officer, Director, 10% o
Insider 61,709,567 89.85% 2026-11-02
Sadiq Khan
Chief Commercial Officer
Insider 1,169,618 1.70% 2025-06-27
Kirti Desai
Chief Financial Officer
Insider 992,983 1.45% 2026-09-14
Curtis L. Patton
Director
Insider 139,192 0.20% 2026-09-11
Jeffrey L. Feike
Director
Insider 131,435 0.19% 2026-09-11
Victor J. Sordillo
Director
Insider 126,539 0.18% 2026-09-11
Keow Lin Goh
Director
Insider 123,678 0.18% 2026-09-11
Susan M Podlogar
Director
Insider 123,678 0.18% 2026-09-11
Neal Flomenberg
Officer
Insider 76,940 0.11% 2026-03-10

Share count 68,678,743 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full TVGN picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for TVGN and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.